CHRS Coherus BioSciences Inc.

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences Announces New Employment Inducement Grants

REDWOOD CITY, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective October 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 64,500 shares of the common stock of the Company to eight newly hired employees with a per share exercise price of $3.54, the closing trading price on the grant date.

The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.

Coherus BioSciences Contact Information:

IR Contact

Jodi Sievers

Coherus BioSciences, Inc.



EN
24/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE

Coherus Oncology Reports Second Quarter 2025 Financial Results and Pro...

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent b...

 PRESS RELEASE

Coherus Oncology to Report Second Quarter 2025 Financial Results on Au...

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of t...

 PRESS RELEASE

Coherus Completes Strategic Transformation to Coherus Oncology, Focusi...

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and ...

Coherus Biosciences Inc: 1 director

A director at Coherus Biosciences Inc sold 99,988 shares at 0.739USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

Coherus Announces Clinical Collaboration with STORM Therapeutics to Ev...

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) – First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch